Oregon is currently home to 1215 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Portland, Eugene, Medford and Clackamas. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis
NCT04891640
Recruiting
This randomized pragmatic trial will generate knowledge about strategies used to de-escalate tumor necrosis factor inhibitor (TNFi) therapy in patients with juvenile spondyloarthritis with sustained inactive disease and are treated at one of the 29 participating pediatric healthcare systems. This open label study will be conducted in the setting of routine clinical care and will compare the risk and timing of flare (Aim 1) and patients' lived experiences (Aim 2) across three arms.
Gender:
ALL
Ages:
Between 8 years and 21 years
Trial Updated:
08/02/2024
Locations: Randall Children's Hospital at Legacy Emanuel, Portland, Oregon
Conditions: Juvenile Spondyloarthritis
Register for Updates
Pain Self-Management and Patient-Oriented Dosing for Pain and in Retention Opioid Treatment
NCT06367387
Recruiting
This study seeks to improve the treatment of chronic pain in people who are taking buprenorphine (also known as Suboxone, Subutex, Zubsolv). The research study is testing two different interventions along with usual clinical care: 1. Pain Self-Management (PSM): an educational program in which individuals with chronic pain work with a trained pain coach and a pain peer to explore strategies to effectively manage the daily problems that arise from chronic pain. 2. Patient-Oriented Dosing (POD):... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2024
Locations: Central City Concern (CCC), Portland, Oregon
Conditions: Opioid Use Disorder, Chronic Pain
Register for Updates
The Influence of Sleep on Cardiovascular Outcomes
NCT06535178
Recruiting
The goal of this study is to identify the effects of sleep regularity on cardiovascular regulatory mechanisms. The investigators are hoping to discover if improving the regularity of sleep timing will improve metabolic and vascular health markers. The protocol is a 12-week prospective cohort study that includes both field and in-laboratory data collection in ostensibly healthy male and female adults, aged 18-40years.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
07/31/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Circadian Rhythm, Cardiometabolic Health, Vascular Health
Register for Updates
Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users
NCT03341078
Recruiting
Addiction to methamphetamine is a serious health problem in the United States. Right now, there are no medications that a doctor can give someone to help them stop using methamphetamine. More research is needed to develop drugs for methamphetamine addiction. Ibudilast (the study drug) is a drug that could help people addicted to methamphetamine.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
07/31/2024
Locations: VA Portland Health Care System, Portland, OR, Portland, Oregon
Conditions: Methamphetamine-dependence
Register for Updates
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
NCT05546580
Recruiting
Iadademstat is being studied as a treatment for subjects with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+). During the trial, iadademstat will be given in combination with gilteritinib, a drug that is already approved to treat patients with FLT3-mutated R/R AML.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/26/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Register for Updates
A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C
NCT05975021
Recruiting
The current trial aims to assess the effect of istaroxime in patients with SCAI Stage C Cardiogenic Shock (CS). These patients look unwell, frequently with a sudden change in mental status, mottled and cool extremities, and delayed capillary refill, as well as signs of congestion and relative low blood pressure and signs of hypoperfusion (reduced oxygen to organs) which frequently require support with rescue therapies including inotropes, vasopressors, or mechanical devices. Windtree Therapeuti... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/24/2024
Locations: Oregon Health and Sciences University, Portland, Oregon
Conditions: Cardiogenic Shock
Register for Updates
Defining Treatment Outcomes and Genetic Architecture in Idiopathic Toe Walking*
NCT06305689
Recruiting
To compare and contrast the clinical, gait and parent-reported outcomes following either non-operative (casting) or operative treatment for children with idiopathic toe walking (ITW) and determine whether there are specific genes associated with ITW.
Gender:
ALL
Ages:
Between 6 years and 18 years
Trial Updated:
07/23/2024
Locations: Shriners Hospitals for Children, Portland, Oregon
Conditions: Idiopathic Toe Walking
Register for Updates
Patterned Multichannel Vibrotactile Stimulation for the Longitudinal Treatment of Moderate Stage Parkinson's Disease
NCT05830110
Recruiting
The purpose of the present research is to examine the effectiveness of a non-invasive, vibrotactile stimulation protocol, known as coordinated reset (CR), for the alleviation of motor symptoms in patients with Parkinson's disease (PD). PD patients exhibit rigidity, slowness (bradykinesia) and poverty (akinesia) of movement as well as other symptoms. Treatment for PD is either pharmacological (first line) or invasive deep brain stimulation. The non-invasive, vibrotactile stimulation approach uses... Read More
Gender:
ALL
Ages:
Between 45 years and 90 years
Trial Updated:
07/23/2024
Locations: Synergic Medical Technologies, Eugene, Oregon
Conditions: Parkinson's Disease
Register for Updates
Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
NCT01484678
Recruiting
The purpose of this research study is to determine the potential of magnetic resonance imaging, spectroscopy, and whole body imaging to monitor disease progression and to serve as an objective outcome measure for clinical trials in Muscular Dystrophy (MD). The investigators will compare the muscles of ambulatory or non-ambulatory boys/men with DMD with muscles of healthy individuals of the same age and monitor disease progression in those with DMD over a 5-10 year period. The amount of muscle d... Read More
Gender:
MALE
Ages:
Between 5 years and 62 years
Trial Updated:
07/23/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
Register for Updates
MYLUNG Consortium Part 3: Observational Study
NCT05885698
Recruiting
This longitudinal study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2024
Locations: Willamette Valley Cancer Institute and Research Center, Eugene, Oregon
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Mechanisms of Risky Alcohol Use in Young Adults: Linking Sleep to Reward- and Stress-Related Brain Function
NCT05684094
Recruiting
This research will use biobehavioral approaches to generate understanding about the linkages between stressful life events, sleep duration and timing, and alcohol use in young adults, with a long-term aim of developing effective preventative interventions for alcohol use disorders.
Gender:
ALL
Ages:
Between 18 years and 24 years
Trial Updated:
07/17/2024
Locations: Oregon Sleep Lab, Eugene, Oregon
Conditions: Alcohol Use Disorder
Register for Updates
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT04198766
Recruiting
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2024
Locations: Providence Portland Medical Center, Portland, Oregon
Conditions: Solid Tumor, Non-Small Cell Lung Cancer, Melanoma, Head and Neck Cancer, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
Register for Updates